Literature DB >> 16620000

Impact of antibiotic administrative restrictions on trends in antibiotic resistance.

D A Marshall1, A McGeer, J Gough, P Grootendorst, M Buitendyk, S Simonyi, K Green, B Jaszewski, S M MacLeod, D E Low.   

Abstract

CONTEXT: In March 2001, in response to concerns about increasing resistance to fluoroquinolone (FQ) antibiotics, the Ontario Drug Benefit (ODB) program limited reimbursement of FQs to ODB beneficiaries defined as high risk or in whom other therapies are not tolerated.
OBJECTIVE: To analyze the impact of the limited use (LU) policy changes on antibiotic resistance rates in Ontario, focussing on community-acquired pathogens.
DESIGN: Ontario data submitted to the Canadian Bacterial Surveillance Network (CBSN) between January 1, 1998 and June 30, 2002 were analyzed for rates of resistance in various pathogen-antibiotic combinations. The effect of the LU policy on the level and rate of change of antibiotic resistance was estimated using time series models.
RESULTS: Resistance rates for S. pneumoniae were 10-12% for penicillin, erythromycin and trimethoprim sulfamethoxazole (TMP/SMX) and less than 3% for amoxicillin and all three FQs tested. There was a statistically significant increasing trend in resistance rates of S. pneumoniae to amoxicillin and levofloxacin throughout the study period. Antibiotic resistance of S. pneumoniae to ciprofloxacin indicated a statistically significant decreasing trend over the study period with a statistically significant increase in the level of antibiotic resistance at the time of the LU policy implementation. No other indication of any statistically significant decrease in resistance rates associated with the LU policy was found.
CONCLUSIONS: Although no direct cause and effect can be proven with these observational data, there is no evidence that the limited use policy to restrict fluoroquinolones decreased antibiotic resistance in any of the pathogen-antibiotic combinations tested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16620000

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  4 in total

1.  Empyema: an increasing concern in Canada.

Authors:  Christian Finley; Joanne Clifton; J Mark Fitzgerald; John Yee
Journal:  Can Respir J       Date:  2008-03       Impact factor: 2.409

2.  Hospital-Acquired Infections After Cardiac Surgery and Current Physician Practices: A Retrospective Cohort Study.

Authors:  Scott O'Keefe; Kenneth Williams; Jean-Francois Legare
Journal:  J Clin Med Res       Date:  2016-11-24

3.  Does variation among provincial drug formulary antimicrobial listings in Canada influence prescribing rates?

Authors:  Shiona K Glass-Kaastra; Rita Finley; Jim Hutchinson; David M Patrick; Karl Weiss; John Conly
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

4.  Resveratrol Antagonizes Antimicrobial Lethality and Stimulates Recovery of Bacterial Mutants.

Authors:  Yuanli Liu; Jinan Zhou; Yilin Qu; Xinguang Yang; Guojing Shi; Xiuhong Wang; Yuzhi Hong; Karl Drlica; Xilin Zhao
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.